Research programme: anti-infectives - Redx Pharma

Drug Profile

Research programme: anti-infectives - Redx Pharma

Latest Information Update: 16 Jul 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Redx Pharma
  • Class Small molecules
  • Mechanism of Action DNA gyrase modulators; Immunomodulators; Neuraminidase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Research Gram-negative infections; Gram-positive infections; Hepatitis B; Influenza virus infections
  • No development reported Bacterial infections

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for research development in Bacterial-infections in United Kingdom
  • 18 Sep 2014 Research programme: anti-infectives - Redx Pharma is available for licensing as of 18 Sep 2014.
  • 18 Sep 2014 Early research in Gram-negative infections in United Kingdom (unspecified route) prior to September 2014
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top